ACURIS SCIENCE

← Back to GLP-1 Metabolic Peptides

Retatrutide | CAS: Available Upon Request

CAS Number:
Available Upon Request
Chemical Classification:
Research peptide

Search related CAS →

Retatrutide occupies a distinct niche among investigational incretin tools as a peptide agonist that engages GLP-1, GIP, and glucagon receptors within a single molecular scaffold. The triple-receptor profile allows laboratories to partition thermogenic, hepatic lipid-oxidation, and insulinotropic outputs in ways that dual or selective agonists cannot replicate, though experimental interpretation depends heavily on species, dose, and receptor-expression context. Research groups differ in emphasis—some prioritize indirect calorimetry endpoints, others focus on liver triglyceride flux or triple-receptor occupancy modeling in cell panels. Practical use spans multi-day rodent metabolic cage studies, hepatocyte lipid-loading assays with hormone profiling, and receptor-knockout backgrounds that attribute phenotypes to individual targets. Characterization follows COA, LC-MS, HPLC, and NMR standards; supplied exclusively for controlled laboratory research.

CAS
Available Upon Request
Molecular Formula
C267H402N64O78
Molecular Weight
6021.0 g/mol
Purity
≥98%
Appearance
White lyophilized powder
Storage
Store at -20°C

Analytical Documentation

COA✓ Available
LC-MS✓ Available
HPLC✓ Available
NMR✓ Available

Research Inquiry

Overview

Retatrutide is a synthetic peptide investigational compound designed as a triple agonist of glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide, and glucagon receptors. Built on an optimized incretin backbone with strategic amino acid substitutions and lipidation, it represents an advanced pharmacological tool for probing how simultaneous activation of three distinct class B GPCRs orchestrates energy expenditure, lipid oxidation, and glycemic control in research models. Unlike dual incretin agonists, retatrutide incorporates glucagon receptor activity, enabling separation of thermogenic and hepatic lipid metabolism effects from pure incretin signaling. Its use in laboratory settings focuses on mapping multi-receptor synergy, receptor occupancy trade-offs, and downstream transcriptional programs in liver, adipose, and hypothalamic tissues under controlled experimental conditions. Supplied at ≥98% purity (C267H402N64O78; 6021.0 g/mol), this material supports controlled laboratory investigation under research-use-only conditions.

Mechanism of Action

Retatrutide engages GLP-1R and GIPR through Gs-coupled cAMP elevation, reproducing insulinotropic and glucagon-suppressive profiles similar to dual incretin agonists in hyperglycemic research conditions. Concurrent glucagon receptor activation stimulates hepatic glycogenolysis and gluconeogenesis at low exposure while promoting fatty acid oxidation and energy expenditure in adipose and brown adipose depots at higher receptor occupancy. The balance among these pathways produces complex net effects on plasma glucose that depend on dose, species, and nutritional state in animal research. Central receptor populations integrate satiety signaling from incretin arms with glucagon-driven autonomic outputs affecting thermogenesis. Retatrutide thus enables hypothesis testing about whether glucagon co-agonism ameliorates or amplifies incretin-associated adiposity changes in long-duration rodent studies.

Receptor Binding & Signaling

Retatrutide binds GLP-1R, GIPR, and glucagon receptor with balanced nanomolar potencies in transfected cell cAMP assays, distinguishing it from selective incretin or glucagon peptides. Selectivity panels at research-relevant concentrations show minimal off-target activity at unrelated peptide hormone receptors. Lipidation modulates free peptide fraction and tissue distribution kinetics in pharmacokinetic studies without altering intrinsic receptor affinity. Species differences in glucagon receptor sequence affect potency translation between human cell lines and rodent in vivo models. Biased signaling metrics vary by receptor type, supporting multi-pathway decomposition in systems biology analyses.

Research Applications

Triple-receptor occupancy modeling

Researchers use retatrutide in parallel cell lines expressing individual receptors to deconvolute contribution of each target to composite signaling readouts. Mixed agonism assays compare cAMP, calcium, and beta-arrestin responses against selective GLP-1, GIP, and glucagon reference peptides. Computational models fit multi-receptor occupancy to predict net hepatic glucose flux under varying peptide concentrations. These frameworks support medicinal chemistry optimization of triple agonist scaffolds in discovery research. Retatrutide serves as a benchmark ligand for validating receptor-resolved assay panels.

Energy expenditure and thermogenesis

Indirect calorimetry chambers and brown adipose tissue UCP1 expression studies employ retatrutide to isolate glucagon-driven thermogenic components from incretin-mediated appetite effects. Pairing with receptor knockdown or antagonist tools attributes oxygen consumption changes to specific pathways. Cold exposure and high-fat feeding models test whether triple agonism modifies adaptive thermogenesis differently from dual incretin compounds. Ex vivo adipocyte respiration measurements complement whole-animal data. Research focuses on mechanistic physiology rather than weight management claims.

Hepatic lipid metabolism platforms

Primary hepatocyte and perfused liver systems expose tissues to retatrutide to evaluate glucagon receptor-mediated VLDL secretion, beta-oxidation enzyme induction, and ketogenesis relative to incretin-driven insulin signaling. Tracer studies with palmitate or oleate trace lipid routing under clamped hormonal conditions. Retatrutide helps researchers understand how simultaneous glucagon and incretin activation reshapes hepatic transcriptomes in RNA-seq experiments. These studies inform metabolic flux models in academic research settings.

Comparative incretin pharmacology

Head-to-head protocols contrast retatrutide with dual agonists such as tirzepatide to quantify incremental effects of glucagon receptor engagement on glycemia, locomotion, and food intake in rodent research. Standardized dosing regimens and glucose tolerance testing provide structured datasets for meta-analysis across laboratories. Retatrutide supports structure-function studies linking amino acid substitutions to receptor bias profiles. Batch consistency is verified through multi-receptor EC50 reporting on certificates of analysis.

Molecular Information

Sequence & Chain Summary

Multi-amino-acid triple-agonist peptide with incretin-derived scaffold and C-terminal lipidation.

Modification Type

Fatty acid conjugation for albumin binding; sequence substitutions for triple receptor activity.

Structural Notes

Retatrutide's extended sequence accommodates helical domains required for engagement with three class B GPCR orthosteric sites, presenting synthesis and folding challenges addressed through stepwise SPPS and preparative chromatography. High-resolution mass spectrometry confirms intact mass and lipid adduct identity. Aggregates may form at high concentration in aqueous buffers, detectable by SEC-HPLC. Membrane-mimetic CD spectroscopy supports helical characterization for structural publications. Purity specifications align with triple-receptor activity QC thresholds. Batch-specific molecular characterization—including mass confirmation and purity profiling—is available through COA, LC-MS, HPLC, and NMR documentation supplied with Retatrutide.

Molecular Formula
C267H402N64O78
Molecular Weight
6021.0 g/mol
Purity Specification
≥98%

Experimental Notes

Stability

Store lyophilized material at −20°C with desiccant protection. Reconstituted retatrutide should be aliquoted and frozen to limit degradation and aggregation during repeated use. Avoid prolonged ambient exposure during multi-step animal dosing preparations. Stability in plasma-containing media depends on protease activity and binding proteins unique to each species studied. Lyophilized Retatrutide should be protected from repeated freeze-thaw cycles, moisture, and prolonged exposure to ambient light where applicable. Analytical integrity is best preserved when material is stored under the conditions specified on the certificate of analysis.

Storage Conditions

Store at -20°C. Retatrutide is supplied as white lyophilized powder. For long-term archival storage in research inventories, maintain sealed containers with desiccant where recommended and document lot numbers for traceability across experimental runs.

Laboratory Handling

Use research-grade solvents and sterile technique for reconstitution. Low-bind plastics reduce peptide loss in dilute working stocks. Document mg-to-nmol conversions using batch-specific molecular weight from COA. Triple-receptor assays require consistent peptide handling to avoid concentration drift across experimental arms. Reconstitute only with appropriate research-grade solvents compatible with your assay format. Allow vials to reach equilibrium before opening, work under clean bench conditions, and label all working solutions with concentration, date, and researcher ID per institutional SOPs.

Related Peptides

GLP-1 Metabolic Peptides →Peptide CAS database →

Frequently Asked Questions

Research-focused answers about Retatrutide. For laboratory use only — not medical advice.

What is Retatrutide used for in research?
Retatrutide supports laboratory investigation of multi-receptor incretin-glucagon pharmacology in qualified preclinical research programs. It is not intended for human or veterinary use, clinical trials outside authorized research channels, or any consumer application. Handle according to institutional chemical safety guidelines.
How does Retatrutide work biologically?
Retatrutide activates GLP-1, GIP, and glucagon receptors concurrently, combining incretin-mediated insulin secretion with glucagon-driven effects on hepatic metabolism and energy expenditure in research models. Net metabolic outcomes depend on dose and nutritional context in experimental designs.
What receptors does Retatrutide interact with?
Primary targets are GLP-1R, GIPR, and the glucagon receptor (GCGR). Off-target activity at unrelated GPCRs is minimal at concentrations typically used in published research assays.
Is Retatrutide stable at room temperature?
Store lyophilized material at −20°C with desiccant protection. Reconstituted retatrutide should be aliquoted and frozen to limit degradation and aggregation during repeated use. Avoid prolonged ambient exposure during multi-step animal dosing preparations. Stability in plasma-containing media depends on protease activity and binding proteins unique to each species studied. For short-term laboratory workflows, minimize time at room temperature and return unused material to recommended storage promptly. Retatrutide is not formulated for ambient long-term storage.
What is the recommended storage condition for Retatrutide?
Store at -20°C. Store lyophilized material in a dedicated −20°C freezer, protect from moisture ingress, and avoid repeated temperature cycling. Reconstituted solutions should be aliquoted and frozen if not used within the validated window of your internal stability study.